Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Peripheral embolism24.01.02.0050.000252%Not Available
Abnormal behaviour19.01.01.0010.000280%Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Feeling of body temperature change08.01.09.0120.000093%Not Available
Erectile dysfunction21.03.01.007; 19.08.04.0010.000606%
Renal injury12.01.05.001; 20.01.03.0150.000093%Not Available
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Parkinson's disease17.01.05.0100.000186%Not Available
Blood disorder01.05.01.004--Not Available
Disease recurrence08.01.03.050--Not Available
Obstructive airways disorder22.03.01.0110.000326%Not Available
Pancreatic enzymes increased13.05.01.004--Not Available
Psychotic disorder19.03.01.0020.000326%
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Poor quality sleep19.02.05.005; 17.15.04.0020.000093%Not Available
Peripheral arterial occlusive disease24.04.03.0100.000093%Not Available
Chorioretinopathy06.09.01.0060.000186%Not Available
Hypophagia07.01.06.010; 19.09.01.004; 14.03.01.0060.000326%Not Available
Gastrointestinal inflammation07.08.03.007--Not Available
Exfoliative rash23.03.07.0060.000093%Not Available
Antinuclear antibody increased13.06.01.004--Not Available
Chronic kidney disease20.01.03.0170.000513%
Infusion site haemorrhage24.07.01.058; 12.07.05.018; 08.02.05.018--Not Available
Bone marrow failure01.03.03.0050.000233%
Loose tooth07.09.05.0090.000186%Not Available
Substance abuse19.07.06.0180.000093%Not Available
Tendon pain15.07.01.0090.000233%Not Available
Liver injury12.01.17.012; 09.01.07.022--Not Available
The 20th Page    First    Pre   20 21 22 23    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene